Nyxoah Raises $3 Million from its At-the-Market Equity Offering


 

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Raises $3 Million from its At-the-Market Equity Offering 

Mont-Saint-Guibert, Belgium – April 13, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $3.0 million in gross proceeds pursuant to the Company’s $50 million at-the-market ('ATM') program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The proceeds will be used for general corporate purposes.

The ordinary shares described above were sold pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-268955), previously filed with the Securities and Exchange Commission (“SEC”) on December 22, 2022, which became effective on January 6, 2023, and a prospectus supplement dated January 6, 2023 and the accompanying prospectus the Company filed with the SEC in connection with the offer and sale of the Company’s common stock pursuant to the Controlled Equity OfferingSM Sales Agreement, dated as of December 22, 2022 with Cantor Fitzgerald & Co., as sales agent (prospectus@cantor.com).

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313


 

Attachment

  • ENGLISH_ATM_FINAL


Nyxoah Raises $3 Million from its At-the-Market Equity Offering

THỦ THUẬT HAY

Cách chặn trang web hiển thị thông báo trên các trình duyệt

Hiện nay các trình duyệt web đều cho phép các trang web hiển thị thông báo tới người dùng. Một cửa sổ pop-up hiện ra hỏi người dùng có muốn nhận thông báo từ trang web hay không. Vậy làm sao để tắt hiển thị thông báo

Đặt Google làm công cụ tìm kiếm mặc định trong Cortana hoặc Start Menu trên Windows 10

Mặc dù nữ trợ lý đã làm tốt trong việc hỗ trợ người dùng, nhưng khi bạn sử dụng Cortana hoặc thanh tìm kiếm trong Start Menu để tìm một thứ gì đó thì kết quả lại được hiển thị ở Microsoft Edge với công cụ

Mở khoá iPhone khi nhập sai mật khẩu quá nhiều lần

Để bảo mật tốt hơn cho người dùng, iPhone sẽ tự động khoá thiết bị nếu nhập mật khẩu khoá màn hình sai quá nhiều lần. Khi này thiết bị sẽ bị vô...

Phát hiện lỗ hổng bảo mật nguy hiểm hơn cả Heartbleed

Shellshock - một lỗ hổng bảo mật nghiêm trọng có khả năng ảnh hưởng đến hàng trăm triệu máy tính, máy chủ và các thiết bị đã được tìm thấy.

Bạn cần làm gì, kiểm tra khi mua iPad Mini 3 cũ?

iPad Mini 3 là chiếc máy tính bảng phổ biến trên thị trường hiện nay. Nhưng không phải người nào cũng có đủ điều kiện để sở hữu chiếc iPad Mini 3 mới. Vì vậy nên người dùng sẽ dễ dàng lựa chọn iPad Mini cũ. Bạn cần làm

ĐÁNH GIÁ NHANH

Đánh giá pin HTC U11: 3000 mAh đủ vượt mặt các siêu phẩm hàng đầu

HTC U11 chỉ có dung lượng pin ở mức trung bình là 3000mAh cho màn hình 5.5 inch Quad HD nhưng nó thực sự có tuổi thọ pin tốt hơn nhiều so với chúng ta mong đợi.

Đánh giá Vivo Y51 – sát thủ phân khúc 3 triệu đồng

Cùng đánh giá Vivo Y51 để xem chiếc smartphone này có xứng đáng là một trong những model smartphone tầm trung đáng sở hữu không nhé!

So sánh thiết kế Sharp Aquos S2 và iPhone X: Những smartphone tiên phong cho xu hướng tràn viền

Trước khi đi vào phần so sánh chi tiết, TCN muốn gửi đến quý độc giả một thông tin. Đó là ngày ra mắt toàn cầu của Sharp Aquos S2 là ngày 8 tháng 8 2017, trong khi đó iPhone X được ra mắt toàn cầu vào ngày 12 tháng 9